Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

Congenital cytomegalovirus (CMV) infection is the most common congenital infection with a birth prevalence of 0.4% in Europe. It is the leading non-genetic cause of sensorineural hearing loss and a major cause of neurodevelopmental disabilities. The risk of intrauterine transmission is highest when primary infection occurs during pregnancy. Primary CMV infection is asymptomatic or causes non-specific symptoms and only serology can diagnose it with certainty.
The diagnosis of CMV infection is based on the combination of 2 or 3 serological markers and the interpretation of the results is more complex than for other infections and may require additional analyses and sometimes delay the diagnosis and the implementation of secondary prevention of CMV transmission to the fetus by the administration of valaciclovir. Indeed, the effectiveness of secondary prevention is conditioned by the early administration of treatment after the maternal primary infection.
The National Reference Center for Congenital CMV Infections at Necker Hospital, in collaboration with the virology laboratory at Paul Brousse Hospital, has developed the MyCMV "expert" tool, which is a decision-making algorithm that allows the interpretation of CMV serology and CMV PCR results.
The hypothesis of the study is that the use and provision of this MyCMV "expert" tool to health professionals (biologists, midwives and obstetricians) for the interpretation of virological results could avoid a delay in diagnosis and would allow patients to be referred more quickly to a prenatal diagnosis center for appropriate management of CMV infection.
The aim of the study is to evaluate the rate of detection of primary CMV infection in the first trimester of pregnancy using the MyCMV tool compared with the reference method (results interpreted by the centre's expert investigator).

开始日期2024-12-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

CTRI/2024/01/061558

/ Not yet recruiting临床4期IIT

A Comparative Study to Assess the Effectiveness of Homoeopathic Medicines Selected on Basis of Totality of Symptoms vis-à-vis Body Language in The Treatment of Chronic Respiratory Diseases - NIL

开始日期2024-01-27

申办/合作机构-

NCT06196398

/ RecruitingN/AIIT

Effects of Medical Treatment of Intracranial Atherosclerotic Diseases Based on Magnetic Resonance Fractional Flow Reserve

This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year.

开始日期2023-01-01

申办/合作机构

首都医科大学宣武医院

100 项与 Nicotinamide riboside/Pterostilbene 相关的临床结果

登录后查看更多信息

100 项与 Nicotinamide riboside/Pterostilbene 相关的转化医学

登录后查看更多信息

100 项与 Nicotinamide riboside/Pterostilbene 相关的专利（医药）

登录后查看更多信息

项与 Nicotinamide riboside/Pterostilbene 相关的文献（医药）

2024-11-01·FOOD RESEARCH INTERNATIONAL

Enhancing the water dispersibility and intestinal targeting of pterostilbene using tannic acid-whey protein conjugates

Article

作者: Zhou, Linlang ; Liang, Xiuping ; Jin, Zhengyu ; Yang, Bohan ; Chen, Long ; Zhang, Yetong ; McClements, David Julian

In this study, three types of whey protein isolate (WPI)-tannic acid (TA) covalent conjugates (WPI-TA) were synthesized via alkaline treatment, free radical-induced method, and laccase induction. These conjugates were subsequently utilized in the antisolvent precipitation method to encapsulate pterostilbene (Pte). The structural and functional properties of these conjugates as carriers for intestinal-targeted Pte delivery were thoroughly evaluated. SDS-PAGE, total phenolic content measurement, grafting efficiency, and FT-IR analysis confirmed the successful formation of three distinct covalent conjugates. Among them, the laccase-induced WPI-TA conjugates exhibited the highest TA grafting efficiency. The particle size of this conjugate was measured at 115.25 nm with a PDI of 0.31. Upon encapsulation of Pte, this conjugate exhibited superior thermal stability, enhanced antioxidant properties, and sustained release within the gastrointestinal tract. The water solubility of Pte in these nanoparticles was found to be 361.19 times higher than that of free Pte, presenting a promising strategy for targeted intestinal delivery of Pte.

2022-10-10·Human molecular genetics

Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301

Article

作者: Casalena, Gabriella ; Fels, Jasmine A ; Konrad, Csaba ; Holmes, Holly E ; Manfredi, Giovanni ; Dellinger, Ryan W

Abstract:

Metabolic alterations shared between the nervous system and skin fibroblasts have emerged in amyotrophic lateral sclerosis (ALS). Recently, we found that a subgroup of sporadic ALS (sALS) fibroblasts (sALS1) is characterized by metabolic profiles distinct from other sALS cases (sALS2) and controls, suggesting that metabolic therapies could be effective in sALS. The metabolic modulators nicotinamide riboside and pterostilbene (EH301) are under clinical development for the treatment of ALS. Here, we studied the transcriptome and metabolome of sALS cells to understand the molecular bases of sALS metabotypes and the impact of EH301. Metabolomics and transcriptomics were investigated at baseline and after EH301 treatment. Moreover, weighted gene coexpression network analysis (WGCNA) was used to investigate the association of the metabolic and clinical features. We found that the sALS1 transcriptome is distinct from sALS2 and that EH301 modifies gene expression differently in sALS1, sALS2 and the controls. Furthermore, EH301 had strong protective effects against metabolic stress, an effect linked to the antiinflammatory and antioxidant pathways. WGCNA revealed that the ALS functional rating scale and metabotypes are associated with gene modules enriched for the cell cycle, immunity, autophagy and metabolic genes, which are modified by EH301. The meta-analysis of publicly available transcriptomic data from induced motor neurons by Answer ALS confirmed the functional associations of genes correlated with disease traits. A subset of genes differentially expressed in sALS fibroblasts was used in a machine learning model to predict disease progression. In conclusion, multiomic analyses highlighted the differential metabolic and transcriptomic profiles in patient-derived fibroblast sALS, which translate into differential responses to the investigational drug EH301.

2019-01-02·Amyotrophic lateral sclerosis & frontotemporal degeneration4区 · 医学

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

4区 · 医学

Article

作者: Dellinger, Ryan W. ; Cuerda-Ballester, María ; Carrera, Sandra ; Benlloch, MarÍa ; Salvador, Rosario ; Sancho-Castillo, Sandra ; Obrador, Elena ; Villaron-Casales, Carlos ; Forner, Alfonso ; de la Rubia, JosÉ E. ; Pascual, Raquel ; Barrios, Carlos ; de Bernardo, Nieves ; JuÁrez, Marta ; Drehmer, Eraci ; Estrela, José M. ; Platero, JosÉ L. ; AlarcÓn, Jorge ; Marchio, Patricia ; Sancho, David ; Caplliure-Llopis, Jordi ; Holmes, Holly E. ; GarcÍa-Pardo, Pilar ; Fuente, Cristian ; Guarente, Leonard

BACKGROUND:

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health's candidate drug EH301 in people with ALS (PALS).

METHODS:

This was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS were recruited thanks to the collaboration of the Spanish Foundation for ALS Research (FUNDELA). Study participants were randomized to receive either EH301 or placebo and underwent evaluation for 4 months. Differences between EH301 and placebo-treated participants were evaluated based on standard clinical endpoints, including the revised ALS functional rating scale (ALSFRS-R), forced vital capacity (FVC), and the Medical Research Council (MRC) grading scale.

RESULTS:

Compared to placebo, participants treated with EH301 demonstrated significant improvements in the ALSFRS-R score, pulmonary function, muscular strength, and in skeletal muscle/fat weight ratio. EH301 was shown to significantly slow the progression of ALS relative to placebo, and even showed improvements in several key outcome measures compared with baseline.

CONCLUSIONS:

This study provides evidence in support of the disease-modifying effects of EH301 for the treatment of ALS.

323

项与 Nicotinamide riboside/Pterostilbene 相关的新闻（医药）

2025-02-10

·微信

ASCO GI丨Anna Dorothea Wagner教授：HER2阳性胃癌靶向治疗新探索，曲妥珠单抗彰显围手术期治疗新希望

编者按：近日，2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）在美国加利福尼亚州旧金山举行。《肿瘤瞭望》特邀瑞士洛桑大学医院Anna Dorothea Wagner教授分享EORTC-1203 GITC临床研究的创新结果，评估了曲妥珠单抗和帕妥珠单抗联合化疗在HER2阳性胃癌围手术期治疗中的疗效。Anna Dorothea Wagner教授指出，尽管EORTC-1203 GITC试验存在一定局限性，但该研究结果揭示了抗HER2靶向治疗在改善HER2阳性胃癌患者生存结局方面的潜力，未来仍需要大规模研究予以验证。Anna Dorothea Wagner教授的研究及其观点为HER2阳性胃癌的精准治疗提供了新的思路和方向。 01 《肿瘤瞭望》：请您介绍一下HER2阳性胃癌的抗HER2治疗现状？ Anna Dorothea Wagner教授：目前，对于不可切除的晚期或转移性HER2阳性胃癌患者，化疗联合曲妥珠单抗或化疗联合曲妥珠单抗+帕博利珠单抗已成为标准治疗策略，并且抗HER2靶向治疗也展现出了显著疗效。众所周知，在HER2阳性乳腺癌患者中，曲妥珠单抗新辅助治疗可将五年总生存率提高约10%。对于局部晚期或转移性胃癌，西方国家也会采用围手术期化疗作为标准治疗方案，手术联合围手术期化疗的五年OS率约为50%。在HER2阳性胃癌患者中，仅在转移阶段进行抗HER2治疗是不合理的，因此对于早期阶段患者，我们开展了EORTC-1203 GITC试验，在围术期治疗中引入靶向治疗手段，以期进一步提升生存率。我们的目标就是通过优化治疗策略，增加患者实现长期缓解的可能性。 Oncology Frontier: Could you please introduce the current status of HER2-targeted treatment for gastric cancer? Dr. Anna Dorothea Wagner: It’s my pleasure to respond to this question. Currently, adding trastuzumab to chemotherapy—either alone or in combination with pembrolizumab—is the standard of care for patients with advanced or metastatic gastric cancers who cannot be cured. Targeting HER2 has also been highly effective in the treatment of both metastatic and localized breast cancer. In breast cancer patients, neoadjuvant trastuzumab improves five-year overall survival by about 10%. For locally advanced or localized gastric cancer, perioperative chemotherapy is the standard of care in Western countries. The overall survival rate with surgery and perioperative chemotherapy is approximately 50% at five years. The idea behind our trial was to improve survival by incorporating targeted therapy for patients with HER2-positive tumors. It seemed inconsistent to offer HER2-targeted therapy only in the metastatic setting and not when patients have a chance of being cured. Our aim was to increase their likelihood of achieving long-term remission. 02 《肿瘤瞭望》：EORTC-1203 GITC研究的设计如何？ Anna Dorothea Wagner教授：本研究为一项开放标签、随机、对照的Ⅱ期临床试验，纳入了来自欧洲、韩国和新加坡37个中心的患者，按1:2:2随机分组，分别予以化疗、化疗+曲妥珠单抗、化疗+曲帕双靶。主要终点为主要病理缓解率（MPR），由两位资深病理学家独立评估，如有分歧，则由第三位专家进行复核。次要终点包括无进展生存期（PFS）和总生存期（OS）。该试验旨在评估在标准围手术期化疗基础上，单独加用曲妥珠单抗或联合使用曲妥珠单抗和帕妥珠单抗，能否将MPR从25%提高到45%。试验方案规定，首先测试双抗体联合方案，如果结果阳性，再进一步考察单抗体方案。图1. 研究设计 Oncology Frontier: What is the design of the EORTC-1203 GITC "INNOVATION" clinical study? Dr. Anna Dorothea Wagner : This was an open-label, randomized phase 2 trial with a 1:2:2 randomization. The study included patients from 37 centers across Europe, South Korea, and Singapore. The primary endpoint was the major pathologic response rate, which was independently assessed by two senior pathologists, with a third expert reviewing discrepancies. Secondary endpoints included progression-free survival and overall survival. The trial was designed to evaluate an improvement in the major pathologic response rate from 25% to 45% by adding trastuzumab alone or a combination of trastuzumab and pertuzumab to standard perioperative chemotherapy. The protocol specified that the double-antibody combination would be tested first, and if positive, the single-antibody approach would be examined. 03 《肿瘤瞭望》：您如何评价本研究中曲妥珠单抗和帕妥珠单抗的表现？ Anna Dorothea Wagner教授：在2015年研究启动时，标准的全身治疗方案为顺铂联合氟尿嘧啶；然而，在2019年FLOT-4试验结果公布后，化疗方案更新为FLOT方案。本研究结果显示，仅在围手术期化疗中加入曲妥珠单抗，总体MPR率较单纯化疗提高了13.7%。具体来说，在接受以FLOT为基础的新辅助治疗患者中，MPR率从33.3%提升至53.3%，我们认为这是一个显著优势。然而，在接受曲帕双靶治疗的患者中，我们观察到的患者获益甚微，未能提高总生存率或总缓解率，这可能与化疗强度的相对降低有关；同时，双靶组的腹泻等不良反发生率显著上升。因此，本研究结果不支持使用曲帕双靶联合化疗的用药方案。图2. EORTC-1203 GITC研究的MPR率在本研究中，单独使用曲妥珠单抗在MPR和PFS方面较单纯化疗表现出了显著获益，3年PFS率的风险比为0.85。其中，在化疗方案修改前接受治疗的患者优势更为显著（HR：0.64）。在化疗方案修改后，这种优势变得不再明显（HR：1.04）。对于3年总生存率，风险比为0.89，其中方案修改前为0.77，修改后为0.99。图3. 化疗方案修改前后的PFS和OS 进一步分析发现，无复发生存期（RFS）与MPR呈强相关性。达到MPR的患者相较于未达到MPR患者，其RFS的风险比为0.26，OS的风险比为0.25，这一结果具有高度相关性。然而，由于样本量相对较小且研究提前终止，MPR的提高并未能转化为具有统计学意义的OS获益。图4. MPR与否对RFS及OS的影响本研究结果应与日本TRIGGER试验以及德国HER-FLOT试验的结果一并考虑。TRIGGER试验显示，对于HER2阳性且有限淋巴结转移的胃癌患者，加用曲妥珠单抗具有生存获益。HER-FLOT试验则显示，接受FLOT联合曲妥珠单抗新辅助治疗患者的3年生存率高达82%，这与本研究中76%的3年生存率结果几乎一致。尽管由于样本量较小且生存结果尚未达到统计学显著性水平，目前尚不能推荐曲妥珠单抗联合化疗作为围手术期标准治疗方案，但该方案较高的缓解率表明，曲妥珠单抗可为肿瘤体积较大的HER2阳性胃癌患者的手术创造有利条件。因此，是否在当前围术期化疗的基础上加入曲妥珠单抗，应依据患者的具体情况，由医生和患者共同权衡利弊后作出决定。 Oncology Frontier: How do you evaluate the performance of trastuzumab and pertuzumab in this study? Dr. Anna Dorothea Wagner : When we initiated the trial in 2015, the standard systemic treatment was a combination of cisplatin and fluoropyrimidine. However, after the publication of the FLOT-4 trial in 2019, the chemotherapy backbone was updated to FLOT. Our findings indicate that adding trastuzumab alone to perioperative chemotherapy increased the major pathologic response rate by 13% overall. Specifically, in patients treated with neoadjuvant FLOT, the response rate improved from 33.3% to 53.3%, which we consider a significant advantage. However, in patients treated with both trastuzumab and pertuzumab, the benefit was marginal, likely due to reduced chemotherapy intensity. Moreover, the double-antibody regimen did not improve overall survival or response rates and was associated with increased toxicity, particularly diarrhea. Therefore, our study does not support the use of this combination. Conversely, trastuzumab alone demonstrated clear benefits in major pathologic response rate and progression-free survival. In the overall patient population, the hazard ratio for progression-free survival was 0.85, with a notable advantage in patients who received the treatment before the amendment (HR: 0.64). However, after the amendment, the benefit was not as pronounced (HR: 1.04). For overall survival, the hazard ratio was 0.89—0.77 before the amendment and 0.99 after. Relapse-free survival showed a strong correlation with major pathologic response. Patients who achieved a major pathologic response had a hazard ratio of 0.26 for relapse-free survival and 0.25 for overall survival, which is highly significant. However, due to the small sample size and premature closure of the study, the improvement in major pathologic response rate did not translate into a statistically significant overall survival benefit. Our study should be viewed in the context of two other trials. The Japanese TRIGGER trial demonstrated a survival benefit of trastuzumab for patients with HER2-positive gastric cancer and limited lymph node metastases. Additionally, the HER-FLOT trial, led by Ralf Hofheinz, reported an impressive three-year survival rate of 82% in patients treated with neoadjuvant FLOT plus trastuzumab, which aligns with our findings of 76% survival at three years. While trastuzumab cannot yet be recommended as a standard addition to perioperative chemotherapy due to the small sample size and lack of significant survival results, its higher response rate suggests that it could be beneficial for patients with large tumors where tumor shrinkage is crucial before surgery. Thus, the decision to add trastuzumab should be made on an individual basis, weighing the potential benefits and risks between doctor and patient. （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

ASCO会议临床2期临床结果

2025-02-08

·全式金生物

助力科研，全式金生物克隆感受态细胞CD201荣登Cell

文章信息文章题目 Identification, structure and agonist design of an androgen membrane receptor 期刊 Cell 发表时间 2025年1月29日主要内容山东大学基础医学院孙金鹏教授团队，联合德国莱比锡大学 Ines Liebscher 教授团队，山东大学易凡教授团队、肖鹏教授团队和于晓教授团队，在 Cell 在线发表了研究论文 Identification, structure and agonist design of an androgen membrane receptor。研究团队筛选鉴定了雄激素 5α-DHT 的膜受体 GPR133/ADGRD1，阐明了其在骨骼肌中的调控作用及分子机制，并发展了特异性 GPR133 的小分子配体，为高效安全的雄激素替代药物开发提供了全新思路。原文链接 https://doi-org.libproxy1.nus.edu.sg/10.1016/j.cell.2025.01.006 使用TransGen产品 Trans5α Chemically Competent Cell (CD201) 研究背景雄激素是主要由男性睾丸和肾上腺皮质分泌的类固醇激素，女性卵巢和肾上腺皮质也会少量分泌，对男女的生理功能都有重要调控作用。雄激素中最主要的睾酮及其代谢产物二氢睾酮，对性器官发育和第二性征形成起决定性作用。同时，二氢睾酮还参与多种代谢和发育过程，在机体多方面生理和病理过程发挥重要作用。雄激素类药物在医学上应用广泛，主要用于治疗雄激素缺乏引起的各种疾病及辅助治疗某些类型贫血。在运动医学领域能增肌、提升运动员肌力和体能。但使用雄激素有显著副作用，限制其药用价值，还被世界反兴奋剂组织列入禁用黑名单，所以科学家一直寻找更安全有效的替代途径。雄激素主要与细胞内雄激素受体结合发挥作用，近年发现其有快速非基因组效应，可能存在膜受体介导的调控过程，不过雄激素的膜受体及作用机制仍是未解之谜。 G 蛋白偶联受体 (GPCR) 是目前最大的膜受体家族，参与几乎所有生理过程，其中粘附类 GPCR 是一个特殊亚家族，我国科学家发现部分粘附类 GPCR 能识别类固醇激素并调控生理功能。这些研究表明类固醇激素可能普遍存在细胞膜受体，与核受体共同调控生理和病理功能。那么，作为类固醇激素明星分子的雄激素，是否能通过结合并激活 GPCR 发挥调控作用呢？文章概述首先，研究团队用高分辨率液相色谱串联质谱分析发现小鼠骨骼肌 (趾长伸肌，EDL) 的 5α-DHT 水平存在性别、年龄和组织特异性差异，且骨骼肌中水平远高于血液。阻断雄激素核受体 (AR) 后，5α-DHT 仍能快速增强肌肉收缩力并使环磷酸腺苷 (cAMP) 水平升高，说明可能通过膜受体调控快速效应。经对骨骼肌 GPCR 高通量筛选，鉴定出 GPR133 为 5α-DHT 的内源膜受体，亲和力达 15.4 nM ，GPR133 基因敲除小鼠对 5α-DHT 的快速肌肉增强效应显著减弱，表明 GPR133 在其中作用重要。随后，研究团队解析 5α-DHT 作用下 GPR133 与 Gs 三聚体复合物的冷冻电镜结构，发现 5α-DHT 在 GPR133 中有高亲和力 “竖直模式” 和低亲和力 “平行模式” 两种结合模式，高亲和竖直结合模式时，靠疏水和极性作用与受体形成稳定作用。进一步分析不同的 aGPCR 与相应类固醇激素配体结合模式，发现 aGPCR 中高度保守基序 “Φ（F/L）2.64 - F3.40 - W6.53” 和 “F7.42××N/D7.46” 分别识别类固醇的疏水核心与极性基团，揭示 aGPCR 识别类固醇激素的普遍规律，也提示可能有更多 aGPCR 是类固醇激素的内源性配体。研究团队还通过基于结构的计算机辅助设计及化学合成，开发出选择性激动 GPR133 的高亲和力小分子化合物 AP503，并阐明其识别结构基础。功能和机制研究显示，AP503 与 5α-DHT 通过激活 GPR133 - Gs - cAMP - PKA 信号轴，促进肌肉收缩相关蛋白磷酸化，快速增强肌肉收缩力。同时，AP503 不激活雄激素核受体，对前列腺等雄激素敏感性器官无明显副作用，能有效区分雄激素膜受体和核受体的调控作用。 5α-DHT 和 AP503 激活 GPR133 的功能及机制研究综上，这项研究鉴定出雄激素 5α-DHT 的膜受体，阐明其激活膜受体促进肌肉收缩的机制，揭示了粘附类受体识别类固醇激素的通用机制。通过发展特异性靶向雄激素膜受体的小分子，可以选择性调控肌肉活性而有效规避雄激素副作用。该研究成果为肌肉萎缩症等疾病治疗提供新靶点，为雄激素替代药物的创新研发提供了理论依据，也为抗衰老研究提供新思路。全式金生物产品支撑优质的试剂是科学研究的利器。全式金生物的克隆感受态细胞 Trans5α Chemically Competent Cell (CD201) 助力本研究。 Trans5α Chemically Competent Cell (CD201) 本产品经特殊工艺制作，可用于 DNA 的化学转化。使用 pUC19 质粒 DNA 检测，转化效率高达 108 cfu/µg DNA 以上，自上市以来多次荣登 Cell、Nature 等知名期刊，助力科学研究。产品特点用于蓝白斑筛选 recA1 和 endA1 的突变有利于克隆 DNA 的稳定和高纯度质粒 DNA 的提取使用 Trans5α Chemically Competent Cell (CD201) 产品发表的部分文章： • Zhao Y, Ping Y Q, Wang M W, et al. Identification, structure and agonist design of an androgen membrane receptor [J]. Cell, 2025. • Wen X, Shang P, Chen H D, et al. Evolutionary study and structural basis of proton sensing by Mus GPR4 and Xenopus GPR4 [J]. Cell, 2025. • Hu Q L, Liu H H, He Y J, et al. Regulatory mechanisms of strigolactone perception in rice [J]. Cell, 2024. • Shang P, Rong N, Jiang J J, et al. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design[J]. Cell, 2023. • Zhong S, Ding W, Sun L, et al. Decoding the development of the human hippocampus[J]. Nature, 2020. • Jiang L, Xie X, Su N, et al. Large Stokes shift fluorescent RNAs for dual-emission fluorescence and bioluminescence imaging in live cells[J]. Nature Methods, 2023. • Li X, Zhang Y, Xu L, et al. Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease[J]. Cell Metabolism, 2023. • Han W, Gao B Q, Zhu J, et al. Design and application of the transformer base editor in mammalian cells and mice[J]. Nature Protocols, 2023. • Liu R, Yao J, Zhou S, et al. Spatiotemporal control of RNA metabolism and CRISPR–Cas functions using engineered photoswitchable RNA-binding proteins[J]. Nature Protocols, 2023. 全式金生物产品再一次登上 Cell 期刊，证明了大家对全式金生物产品品质和实力的认可，也完美诠释了全式金生物一直以来秉承的“品质高于一切，精品服务客户”的理念。全式金生物始终在助力科研的道路上砥砺前行，希望未来能与更多的科研工作者并肩奋斗，用更多更好的产品持续助力科研。

2025-01-31

·生物世界

华人学者本周发表了12篇Cell、Nature及Science论文

编辑丨王多鱼排版丨水成文本周一至周五，华人学者（包括通讯作者和第一作者）在三大顶刊 Cell、Nature、Science 共发表来 10 篇研究论文，其中，2 篇 Cell 论文，7 篇 Nature 论文，3 篇 Science 论文。 2 篇 Cell 论文 1 月 29 日，山东大学基础医学院孙金鹏教授团队，联合德国莱比锡大学 Ines Liebscher 教授团队，山东大学易凡教授团队、肖鹏教授团队和于晓教授团队，在国际顶尖学术期刊 Cell 上发表了题为：Identification, structure and agonist design of an androgen membrane receptor（雄激素膜受体的鉴定、结构和激动剂设计）的研究论文。该研究筛选鉴定了雄激素 5α-DHT 的膜受体 GPR133/ADGRD1，阐明了其在骨骼肌中的调控作用及分子机制，并发展了特异性 GPR133 的小分子配体，为高效安全的雄激素替代药物开发提供了全新思路。 1 月 30 日，复旦大学上海医学院陆路研究员、孙蕾研究员、姜世勃教授团队合作，在国际顶尖学术期刊 Cell 上发表了题为：Early fusion intermediate of ACE2-using coronavirus spike acting as antiviral target（利用ACE2的冠状病毒刺突蛋白早期融合中间体，作为抗病毒靶点）的研究论文。该研究发现了 ACE2 受体诱导的冠状病毒刺突蛋白早期融合中间态构象（E-FIC），并针对该中间态构象设计了高效、广谱、兼具失活病毒和抑制病毒感染的双功能抗冠状病毒候选药物。 7 篇 Nature 论文 1 月 29 日，圣路易斯华盛顿大学栗卫凯、明尼苏达大学 Bin Liu 作为共同通讯作者（Qing Cao 为第一作者），在 Nature 期刊发表了题为：Molecular basis of vitamin K driven γ-carboxylation at membrane interface（维生素K驱动膜界面γ-羧化的分子基础）的研究论文。 1 月 29 日，农业农村部成都沼气科学研究所承磊作为共同通讯作者，在 Nature 期刊发表了题为：Methanol transfer supports metabolic syntrophy between bacteria and archaea（甲醇转移支持细菌和古生菌之间的代谢共生）的研究论文。 1 月 29 日，德克萨斯大学西南医学中心齐晓峰作为通讯作者，在 Nature 期刊发表了题为：Structure and mechanism of vitamin-K-dependent γ-glutamyl carboxylase（维生素 K 依赖型γ-谷氨酰羧化酶的结构与机制）的研究论文。 1 月 29 日，加州大学洛杉矶分校唐奕作为通讯作者，在 Nature 期刊发表了题为：Copper-dependent halogenase catalyses unactivated C−H bond functionalization（铜依赖型卤化酶催化未活化的碳-氢键官能化）的研究论文。 1 月 29 日，河北大学韩兴国作为通讯作者，北京林业大学庾强作为第一作者，在 Nature 期刊发表了题为：Contrasting drought sensitivity of Eurasian and North American grasslands（欧亚大陆和北美草原对干旱敏感性的对比）的研究论文。 1 月 29 日，上海交通大学林尤舜、中国科学院上海生命科学研究院植物生理生态研究所林鸿宣院士作为共同通讯作者，在 Nature 期刊发表了题为：Fine-tuning gibberellin improves rice alkali–thermal tolerance and yield（精细调节赤霉素可提高水稻的耐碱热性和产量）的研究论文。 1 月 29 日，清华大学材料学院林元华、松山湖材料实验室马秀良作为共同通讯作者，在 Nature 期刊发表了题为：Enhanced energy storage in antiferroelectrics via antipolar frustration（通过反极化阻挫增强反铁电体的能量存储）的研究论文。 3 篇 Science 论文 1 月 30 日，中国科学院脑科学与智能技术卓越创新中心（神经科学研究所）刘志勇团队（博士后孙雨薇为第一作者）在 Science 期刊发表了题为：Casz1 is required for both inner hair cell fate stabilization and outer hair cell survival（Casz1 对内毛细胞命运的稳定和外毛细胞的存活都是必需的）的研究论文。 1 月 30 日，马克斯普朗克生物物理研究所 Max Dongsheng Yin 作为第一作者，在Science 期刊发表了题为：Conformational dynamics of a multienzyme complex in anaerobic carbon fixation（厌氧固碳中的多酶复合物的构象动力学）的研究论文。 1 月 31 日，匹茨堡大学 Andrew W. Liu 作为第一作者，在 Science 期刊发表了题为：Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation（抓挠通过神经源性肥大细胞的激活来促进过敏性炎症和宿主防御）的研究论文。论文链接： https://www-cell-com.libproxy1.nus.edu.sg/cell/abstract/S0092-8674(25)00035-2 https://www-cell-com.libproxy1.nus.edu.sg/cell/abstract/S0092-8674(25)00041-8 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-025-08648-1 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-024-08491-w https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-024-08484-9 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-024-08362-4 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-024-08478-7 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-024-08486-7 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41586-024-08505-7 https://www-science-org.libproxy1.nus.edu.sg/doi/10.1126/science.ado4930 https://www-science-org.libproxy1.nus.edu.sg/doi/10.1126/science.adr9672 https://www-science-org.libproxy1.nus.edu.sg/doi/10.1126/science.adn9390 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

100 项与 Nicotinamide riboside/Pterostilbene 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性肾损伤	临床2期	美国	Elysium Health, Inc.初创企业	2020-12-01
主动脉瘤	临床2期	美国	Elysium Health, Inc.初创企业	2020-12-01
肌萎缩侧索硬化	临床1期	欧洲	Elysium Health, Inc.初创企业	-